Chayan Acharya
Overview
Explore the profile of Chayan Acharya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bjornsson M, Acharya C, Strandgarden K, Tiberg F
Clin Pharmacokinet
. 2023 Aug;
62(10):1427-1443.
PMID: 37584841
Background And Objective: In treating opioid use disorder (OUD), subcutaneous (SC) extended-release buprenorphine (BPN) depots, e.g., CAM2038, have been shown to provide smaller and less frequent fluctuations in BPN plasma...
2.
Acharya C, Magnusson M, Vajjah P, Oliver R, Zamacona M
J Clin Pharmacol
. 2022 Dec;
63(4):435-444.
PMID: 36453450
Systemic lupus erythematosus (SLE) is a systemic, autoimmune disease characterized by chronic inflammation and organ damage. Dapirolizumab pegol inhibits CD40 ligand (CD40L) and is currently undergoing phase 3 trials for...
3.
Brekkan A, Lopez-Lazaro L, Yngman G, Plan E, Acharya C, Hooker A, et al.
AAPS J
. 2018 Aug;
20(5):91.
PMID: 30112626
Neutropenia and febrile neutropenia (FN) are serious side effects of cytotoxic chemotherapy which may be alleviated with the administration of recombinant granulocyte colony-stimulating factor (GCSF) derivatives, such as pegfilgrastim (PG)...
4.
Acharya C, Hooker A, Yildiz Turkyilmaz G, Jonsson S, Karlsson M
Comput Methods Programs Biomed
. 2016 Mar;
127:83-93.
PMID: 27000291
Background And Objective: Non-compartmental analysis (NCA) calculates pharmacokinetic (PK) metrics related to the systemic exposure to a drug following administration, e.g. area under the concentration-time curve and peak concentration. We...
5.
Bennett B, Purdy M, Baker K, Acharya C, McIntire W, Stevens R, et al.
Nat Commun
. 2016 Jan;
7:8770.
PMID: 26753910
Gap junction channels mediate intercellular signalling that is crucial in tissue development, homeostasis and pathologic states such as cardiac arrhythmias, cancer and trauma. To explore the mechanism by which Ca(2+)...
6.
Svensson E, Acharya C, Clauson B, Dooley K, Karlsson M
AAPS J
. 2015 Oct;
18(1):171-9.
PMID: 26463060
Pharmacokinetic drug-drug interactions (DDIs) can lead to undesired drug exposure, resulting in insufficient efficacy or aggravated toxicity. Accurate quantification of DDIs is therefore crucial but may be difficult when full...
7.
Acharya C, Kufareva I, Ilatovskiy A, Abagyan R
Biochem Biophys Res Commun
. 2014 Jan;
445(4):717-23.
PMID: 24406170
We developed PeptiSite, a comprehensive and reliable database of biologically and structurally characterized peptide-binding sites, in which each site is represented by an ensemble of its complexes with protein, peptide...
8.
Cunningham C, Hom K, Acharya C, Wilks A, MacKerell Jr A, Coop A
Helv Chim Acta
. 2013 Feb;
93(2):220-226.
PMID: 23378668
The Diels - Alder reaction was applied to 4,5-epoxymorphinan opioids to generate a novel aromatic cycloadduct at C(7) - C(8): Thermolytic cleavage of sultine 8 produced the reactive diene o-quinodimethane...
9.
Petty A, Myshkin E, Qin H, Guo H, Miao H, Tochtrop G, et al.
PLoS One
. 2012 Aug;
7(8):e42120.
PMID: 22916121
During tumor progression, EphA2 receptor can gain ligand-independent pro-oncogenic functions due to Akt activation and reduced ephrin-A ligand engagement. The effects can be reversed by ligand stimulation, which triggers the...
10.
Kolhatkar V, Diao L, Acharya C, MacKerell Jr A, Polli J
J Pharm Sci
. 2011 Nov;
101(1):116-26.
PMID: 22109685
A prodrug approach that employs the human apical sodium dependent bile acid transporter (hASBT) for absorption requires a recognition moiety for hASBT. Bile acids are natural ligands for hASBT, but...